Cancer cure that cures close to 100%

[Guest guest]

Cancer: The Hopes For A Cure Are Temporarily Dashed, But An

Alternative Is Discovered

 

 

 

By Bill Sardi

 

 

 

A prior report, co-authored by Timothy Hubbell and Bill Sardi, posted

at Knowledge of Health (

http://www.knowledgeofhealth.com/blog/kohblog.html ) and on the Lew

Rockwell website (http://www.lewrockwell.com/sardi/sardi84.html ),

aired a heartbreaking problem for cancer patients and their families.

There appears to be a fool-proof cure for cancer unfolding, based

upon human trials with long-term survival and no side effects.

Furthermore, the lead researcher and cancer-cure patent holder, Nobuto

Yamamoto of the Socrates Institute for Therapeutic Immunology in

Philadelphia, claims that more research studies are about to be

published that will further confirm earlier trials.

 

 

 

In addition to two recently published studies showing 16 of 16 breast

cancer patients and 8 of 8 colon cancer patients experienced complete

long-term remissions, lasting 4 to 7 years (Dr. Yamamoto says 7-15

years to be more accurate), (1, 2) from otherwise life-threatening

tumors, Dr. Yamamoto indicates in an email communication that upcoming

reports on his immunotherapy for prostate cancer will be published in

the June issue of Translational Oncology and another report on lung

cancer is in preparation.

 

 

 

But, sadly, the treatment is not available yet. Desperate cancer

patients and their loved ones are dismayed. Dr. Yamamoto indicates

there are current plans " with a pharmaceutical company to establish

clinical trial systems some medical centers. " To the anguish of

cancer patients, just when and where these trials will begin goes

undisclosed.

 

 

 

Intrigue surrounds this discovery. The immunotherapy treatment

involves activating white blood cells known as macrophages which

literally seek out and digest tumor cells. An enzyme excreted from

tumor cells, Nagalase, disarms the macrophages. A naturally produced

molecule, Gc protein, is converted into GcMAF (macrophage activating

factor) under normal conditions, such as when fighting bacterial

infections, to activate macrophages to kill cancer cells. Nagalase

blocks this conversion.

 

 

 

While GcMAF treatment was performed without side effect and with

complete effect for years, Dr. Yamamoto is tinkering with the molecule

in an effort he says will make it more effective in penetrating remote

brain tumors.

 

 

 

The GcMAF molecule is not patentable, but its method of production is

patented by Dr. Yamamoto (U.S. Pat. Nos. 5,177,001 and 5,177,002,

awarded 1993) But why is Dr. Yamamoto altering the GcMAF molecule

when it appeared to work perfectly in prior human trials?

 

 

 

Dr. Yamamoto's newly patented (2006) cancer fighting molecule is

called CdMAF, which stands for cloned GcMAF derivative, which he says

is more stable than, and less immunogenic (allergy provoking), than

another version of CdMAF he has tested. He says " CdMAF is smaller

than 18% of GcMAF, it can rapdly penetrate various membranes/barriers.

Thus it has the most effective to various cancers including brain

cancers. "

 

 

 

But the GcMAF therapy was completely effective, so how Dr. Yamamoto

substantiates the need to improve upon his earlier work, and that

GcMAF when naturally produced in the body works fine, goes unexplained.

 

 

 

The cancer clock is ticking. An estimated 7.6 million people die of

cancer annually (21,000 per hour, more than 850 per minute). Dr.

Yamamoto, through his patents, holds the keys to what appears to be a

bona fide cancer cure. Determining Dr. Yamamoto's time table is a

challenge. Cancer patients have no time to be patient. They inquire

if there are alternatives.

 

 

 

The scientific hint of such an alternative comes in a report published

in Science Daily on May 20, 2008. The report identifies a protein

called IKK(beta) which blocks the activity of a protein that normally

stimulates protective inflammation, but in the context of existing

tumors, it also blocks the activity of a protein that turns on

anti-tumor genes, genes that influence the activation of macrophages.

 

 

 

When scientists inactivated IKK(beta) in macrophages from mouse

tumors, the macrophages went back on the attack. [Retraining immune

cells to kill tumors, Science Daily, May 20, 2008] This means there

is another molecular pathway to the cancer-kill switch outside of Dr.

Nobuto's invention.

 

 

 

The molecular pathway to turn the cancer-kill switch back on is

described in the May 19, 2008 online edition of The Journal of

Experimental Medicine, entitled " Retraining macrophages to kill tumors. "

 

 

 

Here is how the Journal of Experimental Medicine explained this discovery:

Published online May 19, 2008

The Journal of Experimental Medicine, by Hema Bashyam

Retraining macrophages to kill tumors

 

 

Ovarian tumors (blue) are destroyed in mice injected

 

with macrophages in which IKK & #946; signals are inhibited (bottom).

 

Some tumors avoid getting killed by turning macrophages into

immune-suppressive cells. Hagemann et al. now find that these impotent

cells can be reverted into weapons of tumor destruction by simply

suppressing a kinase (enzyme).

 

Macrophages can destroy tumor cells by producing inflammatory

molecules. But macrophages within tumors often secrete harmless

antiinflammatory cytokines and proteins that promote tumor growth.

Tumor cells induce this transformation, but the signals that drive the

conversion were unknown.

 

Hagemann et al. now find that tumor macrophages in mice are disarmed

by signals that activate NFKappaB (NF- & #954;B)—a transcription factor that

normally drives inflammation. As in inflammation, tumor macrophage

NF- & #954;B was turned on by I & #954;B kinase (IKK) & #946;.

 

In tumors, however, IKK & #946; also suppressed STAT1—a transcription factor

that turns on tumor-fighting genes.

 

The basis for this difference is unclear. Perhaps the tumor contains

unique cues that instruct the IKK pathway to shut off STAT1.

 

STAT1 suppression in macrophages depended solely on the cytokine

receptor IL-1R and its downstream adaptor, MyD88, suggesting that

tumors might protect themselves by secreting the IL-1R ligand, IL-1 & #946;.

Macrophages from tumors or from healthy animals became in vivo tumor

killers when engineered to express dominant-negative IKK & #946;. These

reprogrammed macrophages produced high levels of IL-12, which

recruited tumor-fighting NK cells. The group is now investigating

whether infusing similarly reprogramed macrophages into cancer

patients will help reverse tumor growth.

 

Blockage or IKK(beta) activates a different type of macrophage cell,

not the classically activated M1 macrophage produced during infection,

which appears to prevent " the over-exuberant activation of macrophages

during infection. "

 

In a companion report published in the Journal of Experimental

Medicine, researchers report that the NFKappaB pathway critically

controls inflammation and immunity, and that this pathway is

controlled by IKK(beta). While inhibition of IKK(beta) has the

predicted effect of inhibiting inflammation and reducing innate

immunity (immunity produced largely by another white blood cell called

neutrophils), the inhibition or deletion of IKK(beta) produced an

unexpected discovery – greater resistance to infection by activation

of macrophages. (3)

 

Our search for an alternative to GcMAF treatment leads us to locate a

mechanism to inhibit NF-kappaB and IKK(beta). Natural molecules exist

that do this.

 

Nature has an array of NF-KappaB inhibitors, which includes molecules

available as dietary supplements, such as resveratrol, quercetin, EGCG

from green tea. (4)

 

Quercetin (kwer-see-tin), known as a red onion molecule, and

resveratrol (rez-vair-ah-trawl), known as a red wine molecule, are the

most studied NF-KappaB inhibitors

 

Researchers at Seoul National University conducted an experiment where

they employed a chemical (TPA) to induce inflammation in the skin of

mice, which in turn activated NF-kappaB, COX-2 and IKK, molecules that

excite inflammation, a reaction that was " abolished " by resveratrol,

known as a red wine molecule. Researchers concluded that " these

findings suggest that resveratrol targets IKK in blocking

chemically-induced NF-kappaB activation and COX-2 expression in mouse

skin in vivo. " (5)

 

Other studies confirm that resveratrol inhibits activation of the

molecule NF-kappaB. (6,7,8,9)

 

 

 

Researchers at the Universidade Federal de Rio Grande do Sul, Porto

Alegre, RS, Brasil, have carefully documented the effect of quercetin

in an animal study. Chemically-induced diabetes and concomitant

activation of IKK and NF-KappaB was " abolished " by quercetin. (10)

 

 

 

Not only are polyphenols found in red wine, grapes, berries, onions

and tea NF-KappaB inhibitors, but also a whole grain bran factor known

as IP6 (inositol hexaphosphate). (11)

 

Polyphenols like quercetin and resveratrol are also potent enzyme

inhibitors and would likely inhibit Nagalase, the enzyme that

deactivates cancer-cell killing macrophages.

 

Polyphenols favorably inhibit enzymes such as COX-2 (inflammation),

lipase (fat absorption), cytochrome p450 liver enzymes

(detoxification), metalloproteinase (collagen breakdown), telomerase

(enzyme that breaks down the end caps of chromosomes),

5alpha-reductases (hair loss), estrogen sulfotransferase (enzyme that

produces free unbound estrogen), neuraminidase (influenza viral

infection), and likely will be found to inhibit Nagalase, the enzyme

that deactivates cancer-cell killing macrophages.

 

This natural alternative is unproven, but not disproven. According to

the best available evidence, it is a non-harmful, economical approach

to cancer therapy. Given the slow pace of introducing new cancer

therapies like GcMAF, the use of polyphenolic cancer therapy would

appear to be prudent.

 

Polyphenols are of concern to oncologists because pharmacologists

concede that they exhibit the " same metabolic pathways with many

therapeutic drugs " and even make existing drugs work better, but exist

outside the control of drug regulators because they are natural

molecules. (12)

 

Copyright 2008 Bill Sardi, Knowledge of Health, Inc. Bill Sardi has a

commercial interest in the marketing of polyphenolic molecules.

 

References

 

1. Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immunotherapy of

metastatic breast cancer patients with vitamin D-binding

protein-derived macrophage activating factor (GcMAF). International

Journal Cancer 2008 Jan 15; 122(2):461-7.

 

 

 

2. Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y, Immunotherapy

of metastatic colorectal cancer with vitamin D-binding protein-derived

macrophage-activating factor, GcMAF. Cancer Immunology Immunotherapy

2007 Dec 6.

 

3. Fong CHY, Bebian M, Didierlaurent A, et al, An antiinflammatory

role for IKK & #946; through the inhibition of " classical " macrophage

activation. Journal Experimental Medicine, online May 19, 2008.

 

4. Nam NH, Naturally occurring NF-kappaB inhibitors. Mini Review

Medicinal Chemistry 2006 Aug; 6(8):945-51.

 

5. Kundu JK, Shin YK, Kim SH, Surh YJ, Resveratrol inhibits phorbol

ester-induced expression of COX-2 and activation of NF-kappaB in mouse

skin by blocking IkappaB kinase activity. Carcinogenesis 2006 Jul;

27(7):1465-74.

 

6. Chavez E, Reyes-Gordillo K, Segovia J, Resveratrol prevents

fibrosis, NF-kappaB activation and TGF-beta increases induced by

chronic CCl4 treatment in rats. Journal Applied Toxicology, 2008 Jan;

28(1):35-43.

 

 

 

7. Heynekamp JJ, Weber WM, Hunsaker LA, et al, Substituted

trans-stilbenes, including analogues of the natural product

resveratrol, inhibit the human tumor necrosis factor alpha-induced

activation of transcription factor nuclear factor kappaB. Journal

Medicinal Chemistry 2006 Nov 30; 49(24):7182-9.

 

 

 

8. Ma ZH, Ma QY, Wang LC, et al, Effect of resveratrol on NF-kappaB

activity in ratperitoneal macrophages. American Journal Chinese

Medicine 2006; 34(4):623-30.

 

9. Sun C, Hu Y, Liu X, et al, Resveratrol downregulates the

constitutional activation of nuclear factor-kappaB in multiple myeloma

cells, leading to suppression of proliferation and invasion, arrest of

cell cycle, and induction of apoptosis. Cancer Genetics Cytogenetics

165: 9-19, 2006.

 

10. Dias AS, Porawski M, Alonso M, et al, Quercetin decreases

oxidative stress, NF-KappaB activation, and iNOS overexpression in

liver of streptozocotin-induced diabetic rats. Journal Nutrition 2005

Oct; 135(10):2299-304.

 

 

 

11. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R, Inositol

hexaphosphate inhibits constitutive activation of NF-KappaB in

androgen-independent human prostate carcinoma DU145 cells. Anticancer

Res. 2003 Sep-Oct; 23(5A):3855-61.

 

12. Cermak R, Effect of dietary flavonoids on pathways involved in

drug metabolism. Expert Opinion Drug Metabolism Toxicology 2008; 4:

17-35.

 

This copyrighted report is for exclusive posting at Knowledge of

Health, Inc, and not for posting, or cut-and-pasting at other

websites. While naïve readers may believe they are helping get the

word out about promising cancer cures by posting articles such as this

on other websites, this not only diverts web traffic away from this

website and towards other undeserving websites, but articles like this

are often swiped and posted for reasons of commercial gain via their

ability to generate google click fees.

[Guest guest]

At first glance that would sound extremely encouraging, even though so

far it has not been found that effective in all cancers. Then you

look at the sad fact that it is nowhere near the point of being

available and may never be.

 

The question of why anyone would want to alter something that is

already so effective is obvious and I am surprised that such

knowledgeable people would even ask it:

 

If a substance is not patentable, it cannot be exclusively controlled

and sold by a major pharmaceutical who can afford the almost billion

dollars it takes to get a product through trials and to the market.

 

The question of patentability is no doubt a big reason that no major

pharmaceutical company has not immediately jumped on the bandwagon.

In all likelihood, the high success rate is actually an even stronger

reason.

 

Cancer is an almost $400 billion dollar industry whose continued

profits depends on NOT finding a cure and continuing with treatment

which, like 95% of approved medications, have side effects that often

lead to other conditions which will require more and more medications.

 

Hopefully, more information will be forthcoming so that a home remedy

version, much like oleander soup can be devised, because I seriously

doubt that we will ever see it make it to market with the reported

success rate and lack of side effects.

 

 

oleander soup , " mds9513 " <mds9513 wrote:

>

> Cancer: The Hopes For A Cure Are Temporarily Dashed, But An

> Alternative Is Discovered

>

>

>

> By Bill Sardi

>